Resolution of hepatitis B viremia in a renal transplant recipient treated with alpha-2b interferon

Nephron

Volumn 79, Issue 4, 1998, Pages 469-471

  Post, Anthony B ^a,b   Hricik, Donald E ^a   Sterling, Richard K ^a   Bartucci, Marilyn R ^b   Jacobs, Gretta H ^a   Schulak, James A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Hepatitis B; Interferon; Kidney transplant

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIREMIA;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HLA-DR1 ANTIGEN; HUMANS; INTERFERON ALFA-2B; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; TIME FACTORS;

EID: 0031822822     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045094     Document Type: Article

References (13)

1. Degos F, Lugassy C, Degott C, et al: Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. Gastroenterology 1980;94:151.
2. Nelson SR, Snowden SA, Sutherland S, et al: Outcome of renal transplantation in hepatitis BsAg-positive patients. Nephrol Dial Transplant 1994;9:1320.
3. Pirson Y, Alexandre GPJ, van Ypersele de Strihou C: Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 1977;296:4-194.
4. Fairley CK, Mijch A, Gust ID, et al: The increased risk of fetal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA-positive. Transplantation 1991;52:497.
5. Wong DKH, Cheung AM, O'Rourke K, et al: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993; 119:312.
6. Durlik M, Gaciong Z, Rowinska D, et al: Renal allograft function in patients with chronic viral hepatitis B and C treated with interferon alpha. Transplant Proc 1995;27:958.
7. Grotz W, Gondol FK, Rasenack J, et al: Immenent liver failure in hepatitis-B-positive renal-allograft recipient: Successful therapy with interferon-alpha. Nephrol Dial Transplant 1995;10:1932.
8. Kovarik J, Mayer G, Pohanka E, et al: Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Transplant 1988;45:402.
9. Thervet E, Pol S, Legendre CH, et al: Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. Transplantation 1994;58:625.
10. Rostaing L, Izopet J, Baron E, et al: Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995;59:1426.
11. Ware AJ, Luby JP, Holinger B, et al: Etiology of liver disease in renal-transplant patients. Ann Intern Med 1979;91:364.
12. Pol S, Debure A, Degott C, et al: Chronic hepatitis in kidney allograft recipients. Lancet 1990;335:878.
13. de Franchis R, Meucci G, Vecchi M, et al: The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191.